ESMO Breast 2024 | ctDNA in breast cancer: clinical decision making and future perspectives

Masakazu Toi • 17 May 2024

ESMO Breast 2024

Breast Cancer

Masakazu Toi, MD, PhD, Kyoto University, Kyoto, Japan, comments on the role of circulating tumor DNA (ctDNA) in clinical decision making for both metastatic and primary breast cancer. ctDNA aids in monitoring disease progression, predicting prognosis, and assessing therapeutic response. Despite its promise for personalized oncology, challenges remain in standardizing techniques and integrating them into routine practice, and ongoing efforts aim to improve these processes. This interview took place at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.